Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TVTX Travere Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TVTX
Price (delayed)
$15.22
Market cap
$1.35B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.79
Enterprise value
$1.69B
Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this
Highlights
Travere Therapeutics's gross profit has surged by 79% YoY and by 16% QoQ
The revenue has surged by 76% year-on-year and by 17% since the previous quarter
TVTX's net income is down by 41% year-on-year but it is up by 29% since the previous quarter
The company's EPS rose by 32% QoQ but it fell by 31% YoY
TVTX's equity has dropped by 56% year-on-year and by 44% since the previous quarter
The quick ratio has decreased by 27% YoY
Key stats
What are the main financial stats of TVTX
Market
Valuations
Earnings
Shares outstanding
88.8M
Market cap
$1.35B
Enterprise value
$1.69B
Price to earnings (P/E)
N/A
Price to book (P/B)
41.15
Price to sales (P/S)
4.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.18
Revenue
$273.53M
Gross profit
$262.61M
Operating income
-$227.26M
Net income
-$226.71M
EBIT
-$215.5M
EBITDA
-$169.03M
Free cash flow
-$202.19M
Per share
Balance sheet
Liquidity
EPS
-$2.79
EPS diluted
-$2.79
Free cash flow per share
-$2.29
Book value per share
$0.37
Revenue per share
$3.1
TBVPS
$5.04
Total assets
$548.8M
Total liabilities
$515.98M
Debt
$400.46M
Equity
$32.82M
Working capital
$191.71M
Debt to equity
12.2
Current ratio
2.05
Quick ratio
1.95
Net debt/EBITDA
-2
Margins
Efficiency
Dividend
EBITDA margin
-61.8%
Gross margin
96%
Net margin
-82.9%
Operating margin
-83.1%
Return on assets
-41.2%
Return on equity
-1,184%
Return on invested capital
-34.4%
Return on capital employed
-58.8%
Return on sales
-78.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TVTX stock price
How has the Travere Therapeutics stock price performed over time
Intraday
-1.17%
1 week
1.81%
1 month
-28.04%
1 year
98.44%
YTD
-12.63%
QTD
-15.07%
Financial performance
How have Travere Therapeutics's revenue and profit performed over time
Revenue
$273.53M
Gross profit
$262.61M
Operating income
-$227.26M
Net income
-$226.71M
Gross margin
96%
Net margin
-82.9%
Travere Therapeutics's gross profit has surged by 79% YoY and by 16% QoQ
The revenue has surged by 76% year-on-year and by 17% since the previous quarter
The operating margin has soared by 70% YoY and by 40% from the previous quarter
The operating income has grown by 47% YoY and by 30% from the previous quarter
Price vs fundamentals
How does TVTX's price correlate with its fundamentals
Growth
What is Travere Therapeutics's growth rate over time
Valuation
What is Travere Therapeutics stock price valuation
P/E
N/A
P/B
41.15
P/S
4.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.18
The company's EPS rose by 32% QoQ but it fell by 31% YoY
TVTX's equity has dropped by 56% year-on-year and by 44% since the previous quarter
The revenue has surged by 76% year-on-year and by 17% since the previous quarter
The stock's P/S is 37% below its 5-year quarterly average of 7.8 and 5% below its last 4 quarters average of 5.2
Efficiency
How efficient is Travere Therapeutics business performance
The company's return on assets has shrunk by 93% YoY but it rose by 26% QoQ
The return on invested capital has dropped by 86% year-on-year but it is up by 26% since the previous quarter
The company's return on sales rose by 41% QoQ and by 18% YoY
Travere Therapeutics's return on equity has decreased by 8% QoQ
Dividends
What is TVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TVTX.
Financial health
How did Travere Therapeutics financials performed over time
TVTX's total assets is 6% more than its total liabilities
The quick ratio has decreased by 27% YoY
The company's current ratio fell by 26% YoY
Travere Therapeutics's debt to equity has soared by 124% YoY and by 79% from the previous quarter
TVTX's equity has dropped by 56% year-on-year and by 44% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.